Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Exclusion Criteria

• •1. Pregnant or lactating women, or women of childbearing potential with a positive pregnancy test at baseline.
• •2. Evidence of postoperative recurrence or metastasis.
• •3. Previous anti-tumor therapy, including chemotherapy, radiotherapy, or immunotherapy.
• •4. Positive resection margins identified in postoperative pathology.
• •5. History of other malignancies within the past five years, except certain skin cancers, superficial bladder cancer, in situ cervical or breast cancer.
• •6. Uncontrolled pleural effusion, pericardial effusion, or ascites.
• •7. Severe cardiovascular conditions such as symptomatic coronary artery disease, congestive heart failure (grade ≥ II), uncontrolled arrhythmias, or myocardial infarction within the last 12 months.
• •8. Uncontrolled infection, severe kidney disease, or other significant concurrent diseases.
• •9. Allergic reactions to study drugs.
• •10. Receipt of any anti-tumor therapy within 4 weeks prior to enrollment.
• •11. Administration of live attenuated vaccines within 4 weeks prior to the first study treatment dose or plans to receive such vaccines during the study period.
• •12. Positive HIV antibody, active hepatitis B or C (with specific viral load criteria).
• •13. Positive for COVID-19 nucleic acid or antigen test.
• •14. Other conditions deemed by the investigator to potentially affect patient safety or trial compliance, including serious illnesses requiring treatment, severe laboratory abnormalities, or other social or family reasons.